BioCryst Pharmaceuticals | BCRX - 销售收入



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.75B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


销售 更改 日
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
BioCryst Pharmaceuticals USD 218.25M 188.3M 2026-06
Chugai Pharma JPY 341.6B 19.85B 2026-06
Daiichi Sankyo JPY 574.74B 12.26B 2026-06
DBV Technologies USD 645K 2.13M 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Gilead Sciences USD 7.8B 800M 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
Karyopharm Therapeutics USD 35.07M 987K 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Novavax USD 147.14M 76.69M 2025-12
PTC Therapeutics USD 361M 88M 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06